FMP
Theseus Pharmaceuticals, Inc.
THRX
NASDAQ
Inactive Equity
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
4.07 USD
0.005 (0.123%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Iain D. Dukes DPHIL, M.A.
sector
Healthcare
industry
Biotechnology
website
https://theseusrx.comexchange
NASDAQ
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorpo...
CIK
0001745020
ISIN
US88369M1018
CUSIP
88369M101
Address
245 Main Street
Phone
857 400 9491
Country
US
Employee
38
IPO Date
Oct 7, 2021
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
THRX Financial Summary
CIK
0001745020
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
88369M101
ISIN
US88369M1018
Country
US
Price
4.07
Beta
3.98
Volume Avg.
849.6k
Market Cap
181.5M
Shares
-
52-Week
2.05-12.37
DCF
2.35
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.03
P/B
-
Website
https://theseusrx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest THRX News
It looks like there's no news available.
